Cargando…

P-030: CRIZANLIZUMAB REDUCES ENDOTHELIAL ADHESION OF RED BLOOD CELLS FROM SCD PATIENTS IN STANDARDIZED MICROFLUIDIC PLATFORM: IN VITRO TECHNOLOGY ASSESSMENT

Detalles Bibliográficos
Autores principales:	C., FEDERICI, E., KUCUKAL, R., KOCEVAR, L., GILKEY, S., SERTEL, K., MONCHAMP, A., WOLFE, L., NAYAK, A., BRUEDERLE, J., ZAK, U., GURKAN
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Poster Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426784/ http://dx.doi.org/10.1097/01.HS9.0000873016.07993.e1

Ejemplares similares

P1429: IN VITRO COMPARISON OF THE EFFECTS OF INCLACUMAB VS CRIZANLIZUMAB ON REDUCING ENDOTHELIAL ADHESION OF RED BLOOD CELLS IN STANDARDIZED MICROFLUIDIC PLATFORM
por: Federici, Chiara, et al.
Publicado: (2023)

Successful Treatment of SCD-Related Priapism With Crizanlizumab: A Case Series
por: Idowu, Modupe, et al.
Publicado: (2023)

OcclusionChip: A functional microcapillary occlusion assay complementary to ektacytometry for detection of small-fraction red blood cells with abnormal deformability
por: Man, Yuncheng, et al.
Publicado: (2022)

P1439: EPELEUTON, A NOVEL SYNTHETIC Ω-3 FATTY ACID, REDUCES ENDOTHELIAL ADHESION OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS UNDER PHYSIOLOGICAL FLOW CONDITIONS
por: Hamza, Moayed, et al.
Publicado: (2023)

Antithrombin‐III mitigates thrombin‐mediated endothelial cell contraction and sickle red blood cell adhesion in microscale flow
por: Wulftange, William J., et al.
Publicado: (2022)

P-013: VOXELOTOR REDUCES SICKLE RED BLOOD CELL-MEDIATED HYPOXIC MICROVASCULAR OCCLUSION AS MEASURED BY OCCLUSIONCHIP IN VITRO MICROFLUIDIC ASSAY
por: Z., SEKYONDA, et al.
Publicado: (2022)

Whole blood viscosity and red blood cell adhesion: Potential biomarkers for targeted and curative therapies in sickle cell disease
por: Kucukal, Erdem, et al.
Publicado: (2020)

S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN-LABEL SOLACE-KIDS TRIAL
por: Heeney, M, et al.
Publicado: (2022)

P-006: SICKLE RED BLOOD CELL (RBC)-DERIVED EXTRACELLULAR VESICLES ACTIVATE ENDOTHELIAL CELLS AND ENHANCE SICKLE RBC ADHESION MEDIATED BY VON WILLEBRAND FACTOR
por: R., AN, et al.
Publicado: (2022)

P-040: RED BLOOD CELLS ADHESION AND OCCLUSION INDEX IN A PATIENT WITH SICKLE CELL DISEASE PRIOR AND POST HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
por: K., MINCHAMP, et al.
Publicado: (2022)

P-029: OCCLUSIONCHIP: A FUNCTIONAL MICROCAPILLARY OCCLUSION ASSAY COMPLEMENTARY TO EKTACYTOMETRY FOR ASSESSING RED CELL HEALTH IN SICKLE CELL DISEASE
por: Y., MAN, et al.
Publicado: (2022)

Crizanlizumab: A CRITICAL Drug During a CRITICAL Time?
por: Gue, Ying X., et al.
Publicado: (2021)

S121: REDUCED RATE OF VASO-OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL-WORLD, MANAGED ACCESS PROGRAM (MAP)
por: Silva-Pinto, A, et al.
Publicado: (2022)

S108: A SYSTEMATIC POST-MARKETING (PM) REVIEW OF RARE INFUSION-RELATED REACTIONS (IRRS) PRESENTING AS PAIN EVENTS DURING OR AFTER CRIZANLIZUMAB INFUSION IN PATIENTS WITH SICKLE CELL DISEASE (SCD)
por: Kanter, J, et al.
Publicado: (2022)

Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease
por: Kanter, Julie, et al.
Publicado: (2022)

P1491: REAL-WORLD INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
por: Silva-Pinto, A. C., et al.
Publicado: (2022)

Impact of Crizanlizumab on Acute Medical Care Utilization in the Height of the COVID-19 Pandemic
por: Rao, Shivani, et al.
Publicado: (2021)

Real-World Data of Crizanlizumab in Sickle Cell Disease: A Single-Center Analysis
por: Cheplowitz, Halle, et al.
Publicado: (2023)

UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease
por: Buka, Richard J, et al.
Publicado: (2022)

O-04: INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB IN A REAL-WORLD SETTING: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
por: A., SILVA-PINTO, et al.
Publicado: (2022)

Opération piquet PO 2000-030
por: Royer, J P
Publicado: (2000)

Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date
por: Riley, Tanya R, et al.
Publicado: (2019)

Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis
por: Thom, Howard, et al.
Publicado: (2020)

Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine
por: Migotsky, Michael, et al.
Publicado: (2022)

5610357 REDUCTION IN BLOOD TRANSFUSION BURDEN FOLLOWING INITIATION OF VOXELOTOR OR CRIZANLIZUMAB: A CASE SERIES
por: Baruwa Etti, A., et al.
Publicado: (2023)

Title unknown, CERN-ALEPH-98-030
por: CERN. Geneva. ALEPH
Publicado: (1998)

Title unknown, CERN-ALEPH-2001-030
por: CERN. Geneva. ALEPH
Publicado: (2001)

P02-030 - Unusual CNS manifestation
por: Schuh, E, et al.
Publicado: (2013)

PW01-030 – Pulmonary manifestations of FMF
por: Sargsyan, AV, et al.
Publicado: (2013)

P1480: SPLENIC SEQUESTRATION IS MORE COMMON IN SCD-S/Β0-THAL THAN IN SCD-S/S PATIENTS: RESULTS FROM THE GERMAN SCD REGISTRY
por: Allard, P., et al.
Publicado: (2022)

Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial
por: Leucker, Thorsten M., et al.
Publicado: (2021)

5613436 EXPERT CONSENSUS ON THE MANAGEMENT OF INFUSION-RELATED REACTIONS (IRRS) PRESENTING WITH PAIN IN PATIENTS RECEIVING CRIZANLIZUMAB
por: Kanter, J., et al.
Publicado: (2023)

PB2512: SAFETY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE: INTEGRATED POST-MARKETING SURVEILLANCE ANALYSIS
por: Abboud, Miguel, et al.
Publicado: (2023)

Electromagnetic processes in strong crystalline fields-2005-030
por: Uggerhøj, U, et al.
Publicado: (2005)

AB030. Evolution of phosphodiesterase type 5 inhibitors
por: Moon, Du Geon
Publicado: (2016)

AB030. Penile surgery for premature ejaculation and augmentation
por: Chen, Yu
Publicado: (2018)

SUN-030 Tetraorchidism: A Rare Type of Polyorchidism
por: nagaraja, soumya, et al.
Publicado: (2020)

Heterogeneous Red Blood Cell Adhesion and Deformability in Sickle Cell Disease
por: Alapan, Yunus, et al.
Publicado: (2014)

P103: THE ABNORMAL PRESENCE OF MITOCHONDRIA IN CIRCULATING SCD RED BLOOD CELLS ASSOCIATED WITH STRESS ERYTHROPOIESIS
por: Ramasamy, J, et al.
Publicado: (2022)

P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab
por: Karki, Nabin Raj, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2nvns6uk9ng87upk1jb0f5svpe